Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28032024 | 0.85 | LOXL2 (0.46) | LOXL2MEN1KMT2APLA2G2A | |
| SCHEMBL12481955 | 0.84 | LOXL2 (0.58) | CA1CA2RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL27999944 | 0.84 | RXRA (0.47) | RXRACA1CA2MRGPRX4PKM | |
| SCHEMBL57366 | 0.84 | RXRA (0.47) | RXRACA1CA2MRGPRX4PKM | |
| Carbamic Acid SCHEMBL28062788 | 0.83 | GRIN2D (0.46) | RXRAPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL17077559 | 0.83 | LOXL2 (0.57) | CA1CA2RAB9ASMN1; SMN2NFKB1 | |
| SCHEMBL5270681 | 0.82 | CA1 (0.47) | RXRACA1CA2MRGPRX4PKM | |
| 3,5-Dimethoxybenzoic Acid SCHEMBL6885267 | 0.81 | RXRA (0.53) | RXRACA1CA2MRGPRX4PKM | |
| SCHEMBL3547435 | 0.81 | PLA2G2A (0.46) | RXRACA1CA2MRGPRX4PKM | |
| SCHEMBL7518116 | 0.80 | LOXL2 (0.44) | RXRACA1CA2SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321261-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3321261-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2661425-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2661425-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012094328-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | RXRA 366/4885CA1 1784/4885CA2 1702/4885 |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | RXRA 366/4885CA1 1784/4885CA2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.